Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC8XHQ)

• Drug Name: BTX-A51 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Advanced solid tumour	2A00-2F9Z	Phase 1	[1]
Non-hodgkin lymphoma	2B33.5	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 126558497
  TTD Drug ID: DMC8XHQ

Molecule-Related Drug Atlas

Drug(s) Targeting Casein kinase I alpha (CSNK1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9096594, 3	DM8UOKE	N. A.	N. A.	Patented	[3]
IC261	DMXB95R	Pancreatic cancer	2C10	Preclinical	[4]
D-4476	DMHD3R8	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[5]
PMID24900428C14	DMU4BL2	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Cyclin-dependent kinase 9 (CDK9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flavopiridol	DMKSUOI	Acute myeloid leukaemia	2A60	Phase 2	[7]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[8]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[9]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
CYC065	DM9ODT6	Lymphoma	2A80-2A86	Phase 1	[7]
AZD4573	DMOYPTK	Haematological malignancy	2B33.Y	Phase 1	[7]
TP-1287	DM3Z07E	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
VIP-152	DMBQ5OL	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[12]
AZD7503	DM8XJD2	Non-alcoholic steatohepatitis	DB92.1	Phase 1	[13]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[14]

Drug(s) Targeting Cyclin-dependent kinase 7 (CDK7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[8]
Samuraciclib	DM54FQA	Breast cancer	2C60-2C65	Phase 1/2	[15]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
SY-1365	DMK48PM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
LY3405105	DMB51K2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
SY-5609	DMNW3LH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[14]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[14]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[14]
Pyrazolo-triazine derivative 2	DML6V78	N. A.	N. A.	Patented	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Casein kinase I alpha (CSNK1A1)	TTFQEMX	KC1A_HUMAN	Inhibitor	[2]
Cyclin-dependent kinase 7 (CDK7)	TTQYF7G	CDK7_HUMAN	Inhibitor	[2]
Cyclin-dependent kinase 9 (CDK9)	TT1LVF2	CDK9_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04872166) A Study of BTX-A51 in People With Advanced Solid Tumor or Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of BioTheryX.
• [3] Kinase inhibitors and methods of use thereof. US9096594.
• [4] Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60.
• [5] Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization. Eur J Med Chem. 2012 Oct;56:30-8.
• [6] Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [9] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [10] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [11] Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
• [12] VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023 Feb;37(2):326-338.
• [13] ClinicalTrials.gov (NCT05560607) An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
• [14] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [15] The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023 Jun;128(12):2326-2337.
• [16] CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.
• [17] Clinical pipeline report, company report or official report of Syros Pharmaceuticals.